In 4 Phase III registration trials (3 in patients with partial seizures, N = 1480; 1 in patients with PGTCS, N = 163), perampanel administered to patients already receiving 1-3 concomitant antiepileptic drugs (AEDs) demonstrated statistically superior efficacy compared to placebo in reducing seizure frequency. However, use of perampanel in these studies was associated with a risk of psychiatric and behavioral adverse reactions, including aggression, hostility, irritability, anger, and homicidal ideation and threats. The present study is a post hoc analysis of pooled data from these 4 trials to determine if concomitant treatment with levetiracetam and/or topiramate increased the risk of hostility-and aggression-related AEs. Treatment-emergent AEs (TEAEs) were determined using a "Narrow & Broad" search based on the Medical Dictionary for Regulatory Activities (MedDRA) standard MedDRA query (SMQ) for hostility-and aggression-related events. The rate of hostility-and aggression-related TEAEs was observed to be similar among perampanel-treated patients: a) receiving levetiracetam (N = 340) compared to those not receiving levetiracetam (N = 779); b) receiving topiramate (N = 223) compared to those not receiving topiramate (N = 896); and c) receiving both levetiracetam and topiramate (N = 47) compared to those not receiving levetiracetam and topiramate (N = 1072). Severe and serious TEAEs related to hostility and aggression were rare and occurred at a similar rate regardless of concomitant levetiracetam and/or topiramate therapy. Taken together, these results suggest that concomitant treatment with levetiracetam and/or topiramate has no appreciable effect on the occurrence of hostility-or aggression-related TEAEs in patients receiving perampanel.
Introduction
Perampanel is an orally administered, highly selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist [1, 2] . Approved for adjunctive treatment of partial seizures, with or without secondarily generalized seizures, and for primary generalized tonic-clonic seizures (PGTCS) in patients with epilepsy aged ≥ 12 years [1, 3] , perampanel was studied in 4 doubleblind, placebo-controlled Phase III clinical trials published between 2012 and 2015 [4] [5] [6] [7] . Perampanel was recently approved for monotherapy use for partial seizures in the US. Three of these Phase III studies (Studies 304, 305, and 306) were 19 weeks in duration and were conducted in patients with drug-resistant partial seizures, with or without secondarily generalized seizures, who were receiving 1 to 3 concomitant antiepileptic drugs (AEDs). In all 3 partial seizure studies, perampanel, at once-daily doses ranging from 4 mg to 12 mg, demonstrated statistically superior efficacy compared to placebo in reducing seizure frequency and was generally well tolerated [5] [6] [7] . The fourth Phase III study (Study 332) was 17 weeks in duration and was conducted in patients with drug-resistant PGTCS receiving 1 to 3 concomitant AEDs. Treatment with perampanel was well tolerated and, as in the partial seizure studies, resulted in a significantly greater reduction in seizure frequency compared to placebo [4] .
Although treatment with perampanel was well tolerated overall in the Phase 3 studies, the US Prescribing Information for perampanel includes a boxed warning for serious psychiatric and behavioral reactions [1, 7] . These reactions include "aggression, hostility, irritability, anger, and homicidal ideation and threats," and have been observed in patients Epilepsy & Behavior 75 (2017) [79] [80] [81] [82] [83] [84] [85] both with and without concomitant use of medications associated with hostility and aggression [1, 8] . Additionally, the Warnings and Precautions section of the Prescribing Information notes that patients treated with perampanel have experienced "more hostility-and aggressionrelated adverse reactions that were serious, severe, and led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients" [1] . Ettinger et al. conducted an in-depth post hoc analysis of the safety data from perampanel Phase II and III studies in patients with partial seizures and patients without epilepsy and Phase I patients/volunteers [8] . This analysis demonstrated a dose-related increase in psychiatric TEAEs in patients with partial seizures treated with perampanel at doses of up to 12 mg, while aggression and anger were observed at minimal rates in the patients without epilepsy who were treated with perampanel at doses of up to 8 mg, or in the Phase I patients/volunteers who were treated with perampanel at doses greater than 12 mg [8] .
It is important to note that adverse events (AEs) such as aggression and irritability are not exclusive to perampanel. These AEs have been observed with other commonly prescribed AEDs, including levetiracetam and topiramate, which are both approved for the treatment of partial seizures and PGTCS [9, 10] . In the case of levetiracetam, the Warnings and Precautions section of the US Prescribing Information warns of the risk of "behavioral abnormalities and psychotic symptoms," while also noting that levetiracetam-treated patients are at risk for irritability and aggression [9] . In comparison, topiramate differs in its potentially more mild AE profile and behavioral effects [10] . The fact that these widely used agents confer differing risk profiles for behavioral AEs offers a rationale for comparing related safety outcomes when topiramate or levetiracetam is used in conjunction with perampanel and whether any effects are cumulative. Thus, the purpose of the present study is to evaluate the occurrence of hostility-and aggression-related AEs in the 3 perampanel Phase III partial seizure studies and the Phase III PGTCS study in patients who received perampanel therapy and concomitant treatment with levetiracetam and/or topiramate.
Material and methods

Phase III trials in partial seizures
The design of the 3 Phase III studies of perampanel (Study 304, NCT00699972; Study 305, NCT00699582; and Study 306, NCT00700310) has been described in detail elsewhere [5] [6] [7] . Briefly, inclusion criteria required patients to be at least 12 years old, with a diagnosis of simple or complex partial onset seizures, with or without secondary generalization, according to the 1981 Classification of Epileptic Seizures from the International League Against Epilepsy [11] . Patients were required to have uncontrolled partial onset seizures despite treatment with at least 2 different AEDs within the previous 2 years. Patients were also required to have experienced at least 5 partial seizures while receiving up to 3 AEDs at a stable dose during the 6-week baseline period [5] [6] [7] .
In each study, patients entered the Pre-randomization Phase and were assessed for baseline seizure frequency and eligibility. Following the 6-week Baseline Period, patients were randomized to placebo or perampanel 2, 4, 8, or 12 mg [5] [6] [7] . During the 6-week Titration Period, the perampanel dose was increased by 2 mg per week, from 2 mg/day to the randomly assigned dose, or to the maximum tolerated dose (MTD) if the patient could not tolerate the randomly assigned dose. Patients continued on the dose achieved during titration throughout the 13-week Maintenance Period; they also continued receiving their established concomitant AEDs without modification. Patients completing the Maintenance Period were invited to enter a long-term, open-label extension study. Those who discontinued treatment or who did not enter the extension study had a follow-up visit 4 weeks after the end of therapy [5] [6] [7] .
Phase III trial in primary generalized tonic-clonic seizures (PGTCS)
The Phase III study to evaluate the efficacy and safety of adjunctive perampanel in PGTCS (Study 332, NCT01393743) has been described in detail elsewhere [4] . Patients in this trial were at least 12 years old and had a clinical diagnosis of PGTCS in the setting of idiopathic generalized epilepsy, with or without other subtypes of primary generalized seizures. Patients also had to have experienced at least 3 PGTC seizures during the 8 weeks prior to randomization. Eligible patients were receiving fixed doses of 1-3 AEDs during the 30 days prior to baseline.
The Pre-randomization Phase consisted of 2 periods: Screening (up to 4 weeks) and Baseline (4 or 8 weeks, determined based on the reliability of patients' own records of their seizures during the Screening Period), during which patients were assessed for eligibility to participate in the study. The Randomization Phase consisted of 3 periods: Titration (4 weeks), Maintenance (13 weeks), and Follow-up (4 weeks; only for those patients not enrolling in the Extension Phase). At the start of the Randomization Phase, eligible patients were randomized to the perampanel-or placebo-treatment groups in a 1:1 ratio. During the 4-week Titration Period, patients initially received perampanel 2 mg/day or matching placebo and were up-titrated weekly in 2-mg increments to a target dose of 8 mg/day or the MTD. At the completion of the Titration Period, patients entered the 13-week Maintenance Period on the last dose level achieved at the end of the Titration Period and continued taking this dose once daily for the duration of the Maintenance Period unless adjustments were deemed necessary by the investigator [4] . Patients were invited to enter a 142-week open-label extension. Those who chose not to enter the extension study, or who discontinued treatment during the Maintenance Period, immediately entered the 4-week Follow-Up Period.
Determination of hostility-and aggression-related events
Both serious and non-serious treatment-emergent AEs (TEAEs) were determined based on the Medical Dictionary for Regulatory Activities (MedDRA) standard MedDRA query (SMQ) for hostility-and aggression-related events. The "Narrow" SMQs describe TEAEs most likely to reflect a condition of interest. For the present assessment, these would include TEAEs such as aggression, anger, belligerence, or physical assault. "Broad" SMQs identify all possible events, including those that may be of little or no interest, such as skin laceration. A "Narrow & Broad" SMQ search includes both categories of terms [12, 13] . Relevant medical history (i.e., prior psychiatric and/or aggression history) and concomitant use of levetiracetam and topiramate were reported for those patients with TEAEs identified via the hostility-and aggressionrelated "Narrow" and "Narrow & Broad" SMQs.
Results
Patient disposition
The pooled patient population who entered the double-blind phases of their respective partial seizure studies included 1480 patients: 1038 receiving perampanel and 442 receiving placebo. In the PGTCS study, 163 patients were treated during the double-blind phase: 81 received perampanel and 82 received placebo. Table 1 displays the number of patients in all 4 Phase III studies receiving concomitant levetiracetam (+ LEV) or not (− LEV), receiving concomitant topiramate (+ TOP) or not (− TOP), or receiving both AEDs (+ LEV/+TOP), or not taking both (−LEV/−TOP). Note that there is overlap between groups. In addition to these agents, patients might have been receiving other AEDs, considering the study inclusion criteria called for baseline use of 1 to 3 concomitant AEDs. Although a change in concomitant AEDs was not allowed, several patients did not comply due to multiple reasons. For example, in the LEV group, 1 patient discontinued on Day 44 and another took LEV only as a rescue medication. In the TOP group, 3 patients only started TOP after randomization on Day 1, Day 56, and Day 128, respectively. There were also a handful of patients who changed either the dose or the dosing frequency during the core study. The differences in the rates of these TEAEs were minimal within each of the individual dose groups, and there were no significant differences in these TEAE rates between the total perampanel +LEV and −LEV patients (p = 0.29), or between the total perampanel + TOP and −TOP patients (p = 0.40). The incidence of TEAEs for the total perampanel population was almost identical for the + LEV and + TOP patients (13.8% vs 13.9%) and the − LEV and −TOP patients (11.6% vs 11.8%).
TEAEs: Narrow & Broad SMQs
The results for the +LEV/+TOP patients were heterogeneous, with 33.3% of patients in the 2-mg perampanel group experiencing a relevant TEAE, compared to no patients in the 4-mg perampanel group. The heterogeneity is most likely due to the small number of patients who were receiving both concomitant levetiracetam and topiramate. The results for the total perampanel population indicate that 19.1% of the 47 +LEV/+TOP patients experienced hostility-and aggressionrelated TEAEs, compared with the larger − LEV/−TOP population (n = 1072), in which 11.9% experienced hostility-and aggressionrelated TEAEs (p = 0.14).
The most common TEAE related to aggression and hostility was irritability; this result was seen regardless of patients' use of concomitant levetiracetam (Table 2) , topiramate (Table 3) , or levetiracetam/ topiramate. In the levetiracetam subgroup (patients concomitantly receiving or not receiving levetiracetam), the total perampanel patient population experienced irritability at a slightly higher rate for + LEV compared to − LEV patients (8.2% vs 6.9%). A similar difference was seen in the topiramate subgroup (patients concomitantly receiving or not receiving topiramate), with a slightly higher rate for +TOP compared to − TOP in the total perampanel patient population (9.4% vs 6.8%) and for +LEV/+TOP compared to −LEV/−TOP (10.6% vs 7.2%).
There were only 3 relevant TEAEs reported in patients receiving perampanel + LEV that were not observed in the − LEV group as well, and each of these occurred in only 1 patient: disinhibition (8-mg perampanel), impulse-control disorder (12 mg), and personality disorder (8 mg) ( Table 2) . Hostility-and aggression-related TEAEs occurring only in patients receiving either perampanel or placebo and not receiving levetiracetam (− LEV) included belligerence, hypomania, injury, laceration, personality change, physical assault, psychomotor hyperactivity, and psychotic disorder. A dose relationship was observed in the incidence of relevant TEAEs with regard to perampanel use, as seen in higher TEAE rates in the perampanel 8-mg and 12-mg groups compared to placebo, driven primarily by irritability, aggression, and anger (Fig. 1A, Table 2 ).
Hostility-and aggression-related TEAEs observed only in patients receiving perampanel or placebo and concomitant topiramate (+ TOP) were personality change, injury, and personality disorder ( Table 3) . The TEAEs that occurred only in those patients receiving perampanel or placebo without concomitant topiramate (−TOP) included abnormal behavior, agitation, affect lability, belligerence, disinhibition, hypomania, impulse-control disorder, laceration, paranoia, physical assault, psychomotor hyperactivity, and psychotic disorder ( Table 3) . As with the levetiracetam subgroup, a dose relationship between TEAEs and perampanel treatment was observed in the topiramate subgroup, based on higher TEAE rates in the 8-mg and 12-mg groups versus placebo, driven mainly by irritability, aggression, and anger (Fig. 1B, Table 3 ).
Personality disorder was the only TEAE observed in + LEV/+TOP patients that was not seen in −LEV/−TOP patients as well; it was experienced by a single patient in the 8-mg perampanel group. The TEAEs that were observed in −LEV/−TOP patients and not in +LEV/+TOP patients included abnormal behavior, agitation, affect lability, belligerence, disinhibition, hypomania, impulse-control disorder, injury, laceration, paranoia, personality change, physical assault, psychomotor hyperactivity, and psychotic disorder.
Severe TEAEs: Narrow & Broad SMQs
Severe TEAEs based on Narrow and Broad SMQs for hostility and aggression were infrequent in the pooled data from the 4 Phase III trials of perampanel. For those patients receiving perampanel treatment +LEV or + TOP, the majority of TEAEs were mild or moderate in severity. Severe hostility-and aggression-related TEAEs were observed in 1.2% of the patients in the +LEV subgroup, compared with 1.3% of the patients in the −LEV group ( Table 4 ). All of these severe TEAEs occurred in patients receiving either the 8-mg or 12-mg daily dose of perampanel.
Similar results were observed in the topiramate subgroup. Two (0.9%) of the hostility-and aggression-related TEAEs were rated as severe among patients receiving perampanel +TOP, and 1.3% of the TEAEs reported in perampanel −TOP were designated as severe (Table 4) . Again, 
NOTE: A subject with 2 or more adverse events with the same preferred term is counted only once for that preferred term. A TEAE is defined as an adverse event that either begins on or after the first dose date and up to 30 days after the last dose date of study drug, or begins before the first dose date and increases in severity during the treatment period. MedDRA = Medical Dictionary for Regulatory Activities; SMQ = standardized MedDRA query; TEAE = treatment-emergent adverse event. a MedDRA preferred terms are sorted in descending order of frequency in the total perampanel, placebo, and preferred terms columns. b Subjects treated with perampanel in any study. c Bolded TEAEs are considered narrow SMQ terms [8] . NOTE: A subject with 2 or more adverse events with the same preferred term is counted only once for that preferred term. A TEAE is defined as an adverse event that either begins on or after the first dose date and up to 30 days after the last dose date of study drug, or begins before the first dose date and increases in severity during the treatment period. MedDRA = Medical Dictionary for Regulatory Activities; SMQ = standardized MedDRA query; TEAE = treatment-emergent adverse event. a MedDRA preferred terms are sorted in descending order of frequency in the total perampanel, placebo, and preferred terms columns. b Subjects treated with perampanel in any study. c Bolded TEAEs are considered narrow SMQ terms [8] .
all of the severe TEAEs in this subgroup were seen in patients receiving either 8 mg or 12 mg of perampanel daily. Among the +LEV/+TOP patients, no severe TEAEs related to hostility or aggression were observed (Table 4 ). In the − LEV/−TOP patients, 1.3% of the hostility-and aggression-related TEAEs were rated as severe (all occurring in either the 8-mg or 12-mg group). No placebo patients experienced relevant TEAEs that were rated as severe (Table 4) .
Serious TEAEs: Narrow & Broad SMQs
Few serious TEAEs related to hostility or aggression occurred within the pooled patient population from the 4 Phase III trials. In the levetiracetam subgroup, 2 (0.6%) of the hostility-and aggression-related TEAEs-impulse-control disorder and skin laceration-in patients receiving perampanel +LEV were considered serious (Table 4) . Among those not taking concomitant levetiracetam (−LEV), 5 (0.6%) relevant TEAEs were considered serious: 3 cases of aggression, 1 report of belligerence, and 1 report of psychotic disorder (Table 4) . Whereas there were no serious relevant TEAEs in perampanel-treated patients receiving concomitant topiramate (+ TOP), in patients not receiving topiramate (−TOP) there were 7 TEAEs (0.8%) related to hostility or aggression that were rated as serious: 3 reports of aggression, and 1 report each of belligerence, impulse-control disorder, psychotic disorder, and skin laceration (Table 4) . Patients on perampanel and both levetiracetam and topiramate (+LEV/+TOP) experienced no serious relevant TEAEs; in those not receiving levetiracetam or topiramate (− LEV/−TOP), there were 7 (0.7%) serious hostility-and aggression-related TEAEs: aggression in 3 patients, and belligerence, impulse-control disorder, psychotic disorder, and skin laceration in 1 patient each ( Table 4 ). All of these serious TEAEs in each subgroup were seen in patients receiving either 8 mg or 12 mg of perampanel daily. Three placebo patients experienced a serious TEAE-psychotic disorder in all 3-1 patient each from the −LEV, −TOP, and −LEV/−TOP groups.
TEAEs leading to discontinuation: Narrow & Broad SMQs
Discontinuations due to TEAEs related to hostility or aggression occurred at a low rate in the Phase III trials. Nine perampanel-treated patients (2.6%) in the +LEV group discontinued due to relevant TEAEs (aggression, anger, impulse-control disorder, irritability, and skin laceration) (Table 4 ). In the −LEV group, 1.3% discontinuations arising from relevant TEAEs occurred in perampanel-treated patients (abnormal behavior, aggression, anger, belligerence, irritability, personality change, and psychotic disorder) ( Table 4) . The difference in discontinuation rates due to TEAEs related to hostility or aggression between the + LEV and − LEV groups was not statistically significant (p = 0.10). All perampanel-treated patients who discontinued were receiving either an 8-mg or 12-mg daily dose of perampanel. Four placebo patients in the levetiracetam subgroup discontinued due to relevant TEAEs (Table 4) .
Two perampanel-treated patients (0.9%) in the + TOP group discontinued due to relevant TEAEs (irritability and personality change). One placebo patient discontinued due to personality change (Table 4 ). There were 17 (1.9%) discontinuations in perampaneltreated patients not on topiramate (−TOP) due to abnormal behavior, aggression, anger, belligerence, impulse-control disorder, irritability, psychotic disorder, and skin laceration-while 3 placebo patients (0.7%) discontinued from this subgroup ( Table 4) . The difference in discontinuation rates due to TEAEs related to hostility or aggression between the + TOP and −TOP groups was not statistically significant (p = 0.30). All discontinuations in perampanel-treated patients were in the 8-mg and 12-mg dose groups. There were no discontinuations due to relevant TEAEs in the + LEV/+TOP group, while 19 patients (1.8%) discontinued in the perampanel-treated − LEV/−TOP group due to abnormal behavior, aggression, anger, belligerence, impulsecontrol disorder, irritability, personality change, psychotic disorder, and skin laceration. All of these discontinuing patients were receiving Table 4 Severe TEAEs, serious TEAEs, and TEAEs leading to discontinuation. NOTE: A subject with 2 or more adverse events with the same preferred term is counted only once for that preferred term. A TEAE is defined as an adverse event that either begins on or after the first dose date and up to 30 days after the last dose date of study drug, or begins before the first dose date and increases in severity during the treatment period. LEV = levetiracetam; MedDRA = Medical Dictionary for Regulatory Activities; PBO = placebo; PER = perampanel; TEAE = treatment-emergent adverse event; TOP = topiramate. a MedDRA preferred terms are sorted in descending order of frequency in the −LEV/−TOP perampanel, placebo, and preferred terms columns.
either 8-or 12-mg doses of perampanel. Four placebo patients (0.8%) in the −LEV/−TOP group discontinued due to hostility-and aggressionrelated TEAEs (Table 4) . It should be noted that the occurrence of TEAEs related to aggression and hostility was observed in patients both with and without prior psychiatric history and with and without a prior history of aggressive behavior [1] .
Discussion
As noted in the US Prescribing Information, perampanel is associated with an elevated risk of hostility-and aggression-related AEs, including irritability, aggression, and anger [1] . Indeed, many AEDs have been associated with psychiatric disorders and behavioral disturbances [14] . For example, as discussed in a recent review by Brodie et al., increased rates of irritability, hostility, and/or aggression have been reported with levetiracetam, topiramate, and perampanel [15] . In addition, a 2012 survey of adverse effects in clinical studies of AEDs describes aggression outcomes with levetiracetam and topiramate [16] , while previous studies have also described patients reporting "anger" when taking levetiracetam [17] .
The purpose of the present study was to determine whether concomitant use of perampanel with levetiracetam and/or topiramate in a pooled population of patients with partial seizures or PGTCS was associated with an increased risk of such AEs; this post hoc analysis suggests that it was not. Regardless of the perampanel dose, there were few notable differences in the risk of hostility-and aggression-related TEAEs between patients taking concomitant levetiracetam and those who were not; between patients taking concomitant topiramate and those who were not; and between patients receiving both drugs concomitantly and patients not taking both. Although the incidence of hostility-and aggression-related TEAEs for the total perampanel population is numerically greater in the + LEV/+TOP group compared to − LEV/−TOP group, the difference was not statistically significant. Indeed, the sample size was quite variable between the groups, with the + LEV/+TOP group consisting of 47 patients vs 1072 patients in the − LEV/−TOP group. Comparative analysis between patients on concomitant levetiracetam and those on concomitant topiramate showed little variability in the rate of TEAEs related to hostility and aggression, as did a comparison of patients not on concomitant levetiracetam with those not on concomitant topiramate. The fact that severe TEAEs were observed at the identically low rate-1.3%-among perampanel patients not receiving levetiracetam, not receiving topiramate, and not receiving levetiracetam or topiramate gives additional credence to the reliability of these reported TEAE outcomes. Similar or slightly lower rates were observed in perampanel patients receiving levetiracetam, receiving topiramate, and receiving both.
The study design for the 3 perampanel Phase III trials in patients with partial seizures described in the present analysis excluded patients with any significant psychiatric disorder or those for whom there was a suggestion of a psychotic disorder or recurrent affective disorder, as evidenced by the use of antipsychotic medications or by suicide attempts during the 2 years prior to study entry [5] [6] [7] . The Phase III trial in patients with PGTCS had less stringent exclusion criteria with regard to psychiatric disorders, specifically excluding only those patients with suicidal ideation with intent within the 6 months prior to the second study visit. Formal neuropsychiatric assessments were not part of the screening process for these clinical trials, and therefore it is possible that some patients in these studies may have had prior psychiatric or behavioral histories [8] . A previous publication by Ettinger et al. reported post hoc analyses on data from the 3 perampanel Phase III trials in patients with partial seizures (but not the Phase III PGTCS trial) and examined rates of hostility and aggression TEAEs in the extension studies associated with these trials, as well as in Phase II partial seizure studies and their extensions, and in a large population of patients without epilepsy participating in perampanel studies (primarily patients with Parkinson's disease, neuropathic pain, multiple sclerosis, and migraine headache) [8] . Ettinger et al. provided an estimate of the number of patients with prior psychiatric or behavioral histories in the 3 partial seizure trials: psychiatric history in 40.7% of those receiving perampanel and 60% of those receiving placebo; history of hostility and/or aggression in 12.2% of perampanel-treated patients and 12.0% of patients given placebo [8] . However, since these patient histories depended on patient and family reports, it is entirely possible that these estimates are lower than the true prevalence. That said, complete or partial exclusion of such patients from these clinical trials may not accurately reflect the real-world state of this patient population. In other words, it may tend to represent a smaller group of patients affected by psychiatric and behavioral issues than is actually found among patients with these forms of epilepsy [8] . Indeed, it has been reported that psychiatric and neurological comorbidities are often diagnosed in conjunction with epilepsy, affecting up to 50% of patients [14] . Furthermore, treatment for these comorbidities with antipsychotic, antidepressant, and benzodiazepine medications gives rise to the potential of drug-drug interactions, which may affect safety, including hostility-and aggressionrelated TEAEs. Indeed, in the analysis conducted by Ettinger et al. [8] a large proportion of patients treated with perampanel were also receiving concomitant antipsychotic, antidepressant, and benzodiazepine medications. Physicians should be aware of patients' preexisting psychiatric conditions/medications and monitor them while treating with perampanel.
Regarding limitations to the present study, apart from the uncertainty with respect to the degree to which patients entered the study with prior psychiatric and behavioral histories, a potential confounding factor is variation in concomitant LEV and TOP doses. The average doses of concomitant LEV and TOP across PER dose groups were generally consistent based on approximations of the doses reported by patients. However, no detailed analyses were performed. The most significant limitation relates to the fact that this is a post hoc analysis and, as such, it was not designed specifically to investigate this issue. The study is also limited by the relatively small number of patients in each of the treatment groups analyzed. The patients also could have received concomitant AEDs other than levetiracetam or topiramate, which may not have been accounted for in this analysis.
Conclusions
This post hoc analysis of pooled data from 4 Phase III clinical trials in patients receiving perampanel treatment for partial seizures or PGTCS suggests that concomitant treatment with levetiracetam and/or topiramate did not confer significant additional risk for TEAEs related to hostility or aggression. Perampanel is well tolerated as an adjunctive therapy, including concomitant use with levetiracetam and topiramate. Patients with epilepsy who receive perampanel treatment, and their caregivers, should be aware of the potential for hostility-and aggression-related AEs associated with perampanel treatment, as outlined in the US Prescribing Information boxed warning, especially when taking perampanel at higher doses.
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